GNLX

#3898
Genelux Corporation Common Stock
2.82 USD
+6.82%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
2.81
2.85
Faixa anual
2.25
8.54
Mudança diária
+6.82%
Mudança mensal
+6.82%
Mudança em 6 meses
-48.73%
Mudança anual
+17.01%
Fechamento anterior
2.64
Abrir
2.82
Bid
Ask
Mínimo
2.81
High
2.85
Volume
34
Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
Demonstração de resultados Balanço patrimonial Fluxo de caixa
Valor Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25 TTM

Genelux Corporation

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME.

Notícias